Abbott Labs | StockChase
106
Abbott Labs (ABT-N)

Last Price Recorded: $56.1200 on 2017-11-21

ON STOCKCHASE SINCE Jan 2001

biotechnology/pharmaceutical

Abbott Labs


Signal Opinion Expert

2016-02-04

BUY on WEAKNESS
Abbott Labs (ABT-N)

He likes it.  Everything under healthcare has been under pressure.  Model $39 with a 3% upside.  At $31 he would be very excited.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $38.010
Owned: Unknown

2015-09-17

COMMENT
Abbott Labs (ABT-N)

In the healthcare space, he prefers focusing on the health benefit managers such as an Aetna or United Health Group or some names in the biotech space such as Gilead, etc. The valuation on this one looks decent at 20X forward earnings and the growth rate is about 12%. The stock has dropped off quite a bit, so it is not in the space that he likes. (See Top Picks.)

biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $44.240
Owned: No

2015-05-05

COMMENT
Abbott Labs (ABT-N)

Right now this is more if a consumer and diagnostic company. Has done quite well. Is very, very steady. Have increased their dividends 43 years in a row. A nice holding for somebody who wants to buy something and just stay with it over the long-term. However, the valuation is not cheap. Well-managed and should do well over the long-term.

biotechnology/pharmaceutical
Gordon Reid

President, GoodReid Investment Counsel

Price: $46.850
Owned: No

2015-04-27

BUY on WEAKNESS
Abbott Labs (ABT-N)

He would wait for some sort of correction. Likes this. It is a leader in its field.

biotechnology/pharmaceutical
Peter Brieger

Chairman & Chief Executive Officer, GlobeInvestment Capital Management

Price: $47.490
Owned: Yes

2015-03-05

COMMENT
Abbott Labs (ABT-N)

Has a really good upward trend. It is a little above trend right now. Great long-term chart. Healthcare is a great long-term trend that we are in, and you can’t go wrong. It will probably come back a little bit, but nothing to worry about.

biotechnology/pharmaceutical
Hap (Robert) Sneddon FCSI

Chief Portfolio Manager & Founder, Castlemoore Inc.

Price: $47.440
Owned: No

2014-11-11

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick Oct 29/13. Up 22.2%.) A diversified health company. About 40% of their branded generic business is in emerging markets. They expect to increase that percentage. Also, a large player in the nutritional business. Their 3rd division is medical devices and diagnostics.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $44.250
Owned: Yes

2014-10-14

TOP PICK
Abbott Labs (ABT-N)

Spinning off another division. He loves the drug space, which is free of volatility. His model price is $45, a 10% upside.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $41.060
Owned: Yes

2014-10-07

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick Oct 29/13. Up 13.13%.) A diversified global healthcare company. They have 4 divisions including brand generics which is more focused on emerging markets. Also, have a nutritional business as well as a stents division along with the diagnostic division. Pays a dividend of about 2%.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $41.460
Owned: Yes

2014-09-17

TOP PICK
Abbott Labs (ABT-N)

His model price is $48.91, a 14% upside. Saw that they are going to spin off another company, the gift that keeps on giving. He loves large-cap drug companies. Yield of 2.02%.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc.

Price: $43.380
Owned: Yes

2014-08-29

COMMENT
Abbott Labs (ABT-N)

Doesn’t follow this one too closely. Recent reports indicate they are doing a lot of things to restart their growth.

biotechnology/pharmaceutical
Jennifer Radman

VP & Sr. Portfolio Manager, Caldwell Investment Management

Price: $42.240
Owned: No

2014-07-08

PAST TOP PICK
Abbott Labs (ABT-N)

(Top Pick July 9/13, Up 20.37%) Prefers to stay with this part of the business after the spin out.  This is where the growth is.  They have branded generics which are a growth area in emerging markets.  The just made an acquisition to increase presence in Latin America where pharma should double in the next 5 years.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $41.050
Owned: Yes

2014-04-09

DON'T BUY
Abbott Labs (ABT-N)

This one has outperformed the health care sector over the last few years.  Sees a 15% growth rate on the dividend, but it is low compared to others.  Prefers PFE-N.

biotechnology/pharmaceutical
Stan Wong

Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod

Price: $37.630
Owned: No

2014-02-18

BUY
Abbott Labs (ABT-N)

Growth in large-cap pharmaceutical business is fairly anaemic. There are not a lot of great growth prospects. What he does like about this company is that they have a medical technology business, a nutritionals business as well as a traditional pharmaceutical business i.e. all the components of the healthcare sector. Feels there is some growth from an earnings perspective. (See Top Picks.)

biotechnology/pharmaceutical
Stuart Hinshelwood

US Equities Specialist, BMO Nesbitt Burns

Price: $38.930
Owned: Yes

2014-02-07

BUY
Abbott Labs (ABT-N)

Is this a good time to get into health care stocks and what would you recommend? Likes Abbott Labs (ABT-N) very much. Spun off their pharmaceutical R&D business about 2 years ago and split themselves up into 4 different divisions. If looking at global healthcare companies, you can’t go wrong with something like Johnson & Johnson (JNJ-N). Products are cheap and they can easily raise costs. Also, likes Medtronics (MDT-N) which is a device manufacturer.

biotechnology/pharmaceutical
Michael Bowman

Portfolio Manager, Wickham Investment Management

Price: $37.180
Owned: Unknown

2014-02-04

PAST TOP PICK
Abbott Labs (ABT-N)

(A Top Pick Feb 12/13. Up 7.44%.) Still likes this. Likes their branded pharmaceuticals division. Also, have diagnostics and nutritionals. Company increased their dividend by quite a large amount last quarter. Yield of about 2.5%. Trading at an attractive multiple.

biotechnology/pharmaceutical
Christine Poole

CEO & Managing Director, GlobeInvest Capital Management

Price: $36.250
Owned: Yes

Showing 16 to 30 of 106 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.